EnteroMedics Inc. (NASDAQ:ETRM) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Monday.

Separately, Zacks Investment Research upgraded EnteroMedics from a “hold” rating to a “strong-buy” rating and set a $2.25 target price for the company in a research report on Wednesday, August 23rd.

Shares of EnteroMedics (NASDAQ:ETRM) traded up 1.42% on Monday, hitting $1.79. The company’s stock had a trading volume of 307,186 shares. EnteroMedics has a 52 week low of $0.04 and a 52 week high of $30.41. The firm has a market cap of $18.13 million, a price-to-earnings ratio of 0.03 and a beta of 3.07. The stock’s 50-day moving average price is $1.86 and its 200-day moving average price is $4.09.

EnteroMedics (NASDAQ:ETRM) last issued its quarterly earnings results on Tuesday, August 8th. The medical device company reported ($0.91) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.00) by $0.09. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.20 million. EnteroMedics had a negative return on equity of 167.73% and a negative net margin of 4,399.48%. Equities analysts expect that EnteroMedics will post ($1.77) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.watchlistnews.com/valuengine-lowers-enteromedics-inc-etrm-to-strong-sell/1604022.html.

A hedge fund recently raised its stake in EnteroMedics stock. Vanguard Group Inc. raised its position in EnteroMedics Inc. (NASDAQ:ETRM) by 24.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 49,740 shares of the medical device company’s stock after buying an additional 9,727 shares during the quarter. Vanguard Group Inc. owned about 0.72% of EnteroMedics worth $248,000 at the end of the most recent quarter. 1.28% of the stock is currently owned by institutional investors and hedge funds.

About EnteroMedics

EnteroMedics Inc (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.

Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.